Pharmacokinetics and pharmacodynamics of the enantiomers
of warfarin in man.
Obviousness of Enantiomers
over Prior Art Racemates (126)
To date, there have been several methods disclosed in the literature for preparing d-threo enantiomer
of methylphenidate, the process reported first by Patrick etal, describes use of expensive resolving agent 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate in the resolution of dl-threo- methylphenidate, The Journal of Pharmacology and Experimental Therapeutics,241:152-158(1987).
held that the anticipation argument failed because the genus patent only disclosed the existence of enantiomers
generally; there was no specific disclosure of enantiomers
of the racemic mixture of clopidogrel, nor was there disclosure of how to separate the enantiomers
Therefore, the first aim of this study was to develop and validate an assay for simultaneous measurement of concentrations and ratios of AM, MA, MDA, MDMA, and MDEA enantiomers
in oral fluid.
The most infamous case of the two enantiomers
of a racemic drug being highly different in their effects on the human body is that of thalidomide* The drug was originally released as a means of combating morning sickness, and one enantiomer
was successful at alleviating these symptoms.
ratios (the amount of one enantiomer
expressed as percentage of the total amount of the pair of compounds) of some monoterpenoic compounds in the blackcurrant aroma samples are presented in Table 4.
Inhibition of tyrosine hydroxylase by R and S enantiomers
of salsolinol, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline.
The therapeutic properties of citalopram apparently reside in just one of the enantiomers
Concern over possible or demonstrated negative side effects from one of the enantiomers
has accelerated the effort to market single enantiomer
or chiral pure drugs.
Under the terms of the agreement, Sepracor has exclusively licensed to Janssen all of Sepracor's worldwide rights to develop and market norcisapride enantiomers
CTP-221 has a specific deuterium modification pattern which optimally slows the interconversion of enantiomers
in vivo, thus enabling administration of the more potent S-enantiomer
with minimal exposure to the R-enantiomer